These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 17158386)

  • 1. Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?
    Heine RJ; Diamant M; Mbanya JC; Nathan DM
    BMJ; 2006 Dec; 333(7580):1200-4. PubMed ID: 17158386
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
    Chon S; Rhee SY; Ahn KJ; Baik SH; Park Y; Nam MS; Lee KW; Yoo SJ; Koh G; Lee DH; Kim YS; Woo JT;
    Diabetes Obes Metab; 2018 May; 20(5):1121-1130. PubMed ID: 29272062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Insulin sensitizers].
    Scheen AJ; Paquot N
    Rev Med Liege; 2005; 60(5-6):409-13. PubMed ID: 16035302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes: preventing type 2 diabetes mellitus: is metformin the answer?
    Buchanan TA; Xiang AH
    Nat Rev Endocrinol; 2010 May; 6(5):253-4. PubMed ID: 20414319
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
    Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
    J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones.
    Nathan DM; Buse JB; Davidson MB; Ferrannini E; Holman RR; Sherwin R; Zinman B
    Diabetologia; 2008 Jan; 51(1):8-11. PubMed ID: 18026926
    [No Abstract]   [Full Text] [Related]  

  • 7. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
    Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H
    Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comment on: TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care 2013;36:1749-1757.
    Baldi JC; Manning PJ; Hofman PL; Walker RJ
    Diabetes Care; 2013 Dec; 36(12):e223. PubMed ID: 24265392
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
    Nathan DM; Buse JB; Davidson MB; Heine RJ; Holman RR; Sherwin R; Zinman B; ;
    Diabetologia; 2006 Aug; 49(8):1711-21. PubMed ID: 16802130
    [No Abstract]   [Full Text] [Related]  

  • 10. Comment on: Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49:1711-1721.
    Cerasi E
    Diabetologia; 2007 Mar; 50(3):693-4. PubMed ID: 17187245
    [No Abstract]   [Full Text] [Related]  

  • 11. Changing the treatment paradigm for type 2 diabetes.
    Del Prato S; Penno G; Miccoli R
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S217-22. PubMed ID: 19875555
    [No Abstract]   [Full Text] [Related]  

  • 12. Type 2 diabetes mellitus in youth: the complete picture to date.
    Gungor N; Hannon T; Libman I; Bacha F; Arslanian S
    Pediatr Clin North Am; 2005 Dec; 52(6):1579-609. PubMed ID: 16301084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction.
    Armato J; DeFronzo RA; Abdul-Ghani M; Ruby R
    Endocr Pract; 2012; 18(3):342-50. PubMed ID: 22068250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Mar; 352():i1450. PubMed ID: 27029547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic durability of monotherapy for diabetes.
    Garg R
    N Engl J Med; 2007 Mar; 356(13):1379; author reply 1380. PubMed ID: 17402165
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-Term Weight Loss With Metformin or Lifestyle Intervention.
    Ann Intern Med; 2019 May; 170(10):. PubMed ID: 31009938
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical Inquiry: Does metformin prevent diabetes in at-risk adults?
    Mangahas T; Huang G; Neher J; Safranek S
    J Fam Pract; 2013 Aug; 62(8):436-7. PubMed ID: 24143338
    [No Abstract]   [Full Text] [Related]  

  • 18. Comment on: Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49:1711-1721.
    Cryer PE
    Diabetologia; 2007 Jan; 50(1):222-4; discussion 225-30; author reply 231-3. PubMed ID: 17047916
    [No Abstract]   [Full Text] [Related]  

  • 19. Metformin: effective in the prevention of new-onset type 2 diabetes?
    Drown DJ
    Prog Cardiovasc Nurs; 2008; 23(2):93-4. PubMed ID: 18843833
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical management strategies for type 2 diabetes.
    Cefalu WT; Urquhart S
    JAAPA; 2007 Dec; Suppl():9-14. PubMed ID: 18217246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.